Pfizer Inc. (NYSE:PFE) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Pfizer Inc. (NYSE:PFE) have been assigned a consensus recommendation of “Moderate Buy” from the thirteen analysts that are presently covering the stock, Marketbeat reports. Seven analysts have rated the stock with a hold recommendation, five have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $33.91.

A number of research firms recently weighed in on PFE. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research note on Thursday, October 3rd. Wells Fargo & Company increased their price target on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. Barclays lifted their price objective on Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 31st. Daiwa America raised Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Finally, UBS Group boosted their target price on Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 31st.

Pfizer Price Performance

PFE opened at $29.22 on Friday. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.60. The stock has a market capitalization of $165.58 billion, a P/E ratio of -487.00, a price-to-earnings-growth ratio of 1.02 and a beta of 0.67. The company’s 50 day simple moving average is $29.07 and its 200-day simple moving average is $28.44. Pfizer has a one year low of $25.20 and a one year high of $31.54.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, beating the consensus estimate of $0.46 by $0.14. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The company had revenue of $13.28 billion during the quarter, compared to analysts’ expectations of $12.96 billion. During the same period last year, the firm earned $0.67 EPS. The business’s revenue for the quarter was up 2.1% on a year-over-year basis. Sell-side analysts anticipate that Pfizer will post 2.66 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be issued a $0.42 dividend. This represents a $1.68 annualized dividend and a dividend yield of 5.75%. The ex-dividend date of this dividend is Friday, November 8th. Pfizer’s dividend payout ratio (DPR) is presently -2,800.00%.

Hedge Funds Weigh In On Pfizer

A number of large investors have recently added to or reduced their stakes in the company. Olistico Wealth LLC acquired a new position in shares of Pfizer during the second quarter worth about $25,000. MFA Wealth Advisors LLC acquired a new position in Pfizer during the 2nd quarter worth approximately $29,000. Quarry LP bought a new position in shares of Pfizer during the 2nd quarter worth approximately $31,000. Trivant Custom Portfolio Group LLC raised its holdings in shares of Pfizer by 100.0% in the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 600 shares during the last quarter. Finally, Financial Connections Group Inc. bought a new stake in shares of Pfizer in the second quarter worth $34,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.